Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Irbesartan/Atorvastatin FDC in T2DM with Hyperlipidemia and Hypertension
NCT02842359Phase 4Completed
- Sponsor
- Sanofi
- Start
- Aug 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of irbesartan and atorvastatin in hypertension (HTN) and hyperlipidemia (3 arms), sponsored by Sanofi. Primary endpoint: Flow Mediated Dilation at 4 weeks. Started Aug 2016; status: completed.
02
Drugs
irbesartanatorvastatin
03
Conditions
hypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on NCT02842359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02842359.